Higher serum levels of inflammatory biomarkers, such as C-reactive protein (CRP) and interleukins (IL), particularly IL-6, IL-7, leptin, tumor-necrosis factor α (TNF-α), and transforming growth factor β (TGF-β), are found in patients with NAFLD, and their blood levels correlate with NAFLD progression and prognosis [15,16]. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.